Once considered rare and untreatable, amyloid transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM) has increased in incidence over the last decade and is now a treatable condition. This transformation is due, in part, to our understanding of the biology of the disease and recognition of comorbid or co-occurring conditions in patients with both cardiac and noncardiac amyloidosis. In an open discussion, chairperson Martha Grogan, MD, and faculty members Marianna Fontana, MD, and Nitasha Sarswat, MD, will provide an updated review of the disease state. They will shed light on our shifting understanding of the mechanism of the disease, discuss the pathogenic and protective genetic variants, and share evidence from clinical trials that are impacting the evolving treatment landscape.
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Facebook Comments